

<b>Name</b>	Dr. Nicholas Short
<b>Current Position &amp; Affiliation</b>	Associate Professor
<b>Country</b>	United States
<b>Major Field</b>	Hematology-Oncology (Adult Leukemia)

### Educational Background

May 2022	M.S. in Biomedical Sciences The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences; Houston, Texas
May 2011	MD Baylor College of Medicine; Houston, Texas
Dec 2006	BA in Philosophy Rice University; Houston, Texas

### Professional Experience

<b>Postgraduate Training</b>	
Jul 2014–Jun 2017	Clinical Fellowship, Hematology-Oncology The University of Texas MD Anderson Cancer Center
Jun 2011–Jun 2014	Clinical Residency, Internal Medicine Brigham and Women's Hospital; Boston, Massachusetts
<b>Faculty academic appointments</b>	
Sep 2023–Present	Associate Professor Leukemia The University of Texas MD Anderson Cancer Center
Jul 2017–Aug 2023	Assistant Professor Leukemia The University of Texas MD Anderson Cancer Center

### Other Experience and Professional Membership

Jun 2025–Present	Chair, Institutional Committee Scientific Review Committee (SRC) The University of Texas MD Anderson Cancer Center
2022–Present	Core Development Lead, Institutional Committee ALL and AML Algorithm The University of Texas MD Anderson Cancer Center
2020–Present	Reviewer, Institutional Committee Institutional Research Grant Committee The University of Texas MD Anderson Cancer Center
2019–Present	Member, Institutional Committee Department of Biostatistics New Faculty Selection Committee



	The University of Texas MD Anderson Cancer Center
2018–2019	Faculty Judge, Institutional Committee Trainee Research Day The University of Texas MD Anderson Cancer Center
2018–2020	Faculty Lecturer, Institutional Committee Comprehensive Board Review in Hematology and Medical Oncology The University of Texas MD Anderson Cancer Center
2018–May 2025	Member, Institutional Committee Scientific Review Committee (SRC) The University of Texas MD Anderson Cancer Center
2017–Present	Core Development Team Leader, Institutional Committee Tumor Lysis Syndrome Working Group The University of Texas MD Anderson Cancer Center

### Main Scientific Publications

- Short NJ**, Kantarjian H, Furudate K, Jain N, Ravandi F, Karrar O, Loghavi S, Nasr L, Haddad FG, Senapati J, Garris R, Takahashi K, Jabbour E. Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. *J Hematol Oncol*. 2025 May 14; 18(1):55. PMID: 40369607 <https://doi.org/10.1186/s13045-025-01709-y>.
- Short NJ**, Wierzbowska A, Cluzeau T, Laribi K, Recher C, Czyz J, Ochrem B, Ades L, Gallego-Hernanz MP, Heiblig M, Audisio E, Zarzycka E, Li S, Ferenc N, Yeh T, Faller DV, Sedarati F, Papayannidis C. Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia. *Leuk Lymphoma*. 2024 Nov 28; :1-11. PMID: 39606906 <https://doi.org/10.1080/10428194.2024.2431878>.
- Short NJ**, Nguyen D, Jabbour E, Senapati J, Zeng Z, Issa GC, Abbas H, Nasnas C, Qiao W, Huang X, Borthakur G, Chien K, Haddad FG, Pemmaraju N, Karrar OS, Nguyen D, Konopleva M, Kantarjian H, Ravandi F. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. *Lancet Haematol*. 2024 Nov; 11(11):e839-e849. PMID: 39303729 [https://doi.org/10.1016/S2352-3026\(24\)00250-3](https://doi.org/10.1016/S2352-3026(24)00250-3).
- Short, NJ**, Jabbour, EJ, Nasr, L, Jain, N, Haddad, FG, Issa, GC, Sasaki, K, Senapati, J, Kebriaei, P, Garris, R, Konopleva, M, Ravandi-Kashani, F, Kantarjian, HM. Characteristics and outcomes of patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after failure of a frontline ponatinib-containing therapy. *American journal of hematology*. 2024 Jul 01; 99(7):1423-1426. PMID: 38607091 PMID: PMC11804797.
- Short, NJ**, Jabbour E, Jamison T, Paul S, Cuglievan B, McCall D, Gibson A, Jain N, Haddad FG, Nasr LF, Marx KR, Rausch C, Savoy JM, Garris R, Ravandi F, Kantarjian H. Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. *Clin Lymphoma Myeloma Leuk*. 2024 Apr; 24(4):e168-e173. PMID: 38212207.

- 
6. **Short, NJ**, Jabbour E, Jain N, Senapati J, Nasr L, Haddad FG, Li Z, Hsiao YC, Yang JJ, Pemmaraju N, Ohanian M, Wierda WG, Montalban-Bravo G, Borthakur G, Han L, Xiao L, Huang X, Abramova R, Zhao M, Garris R, Konopleva M, Ravandi F, Kantarjian H. A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. *Blood Adv.* 2024 Feb; 8(4):909-915. PMID: 38207208 PMCID: PMC10875259.
  7. **Short, NJ**, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, Yilmaz M, Borthakur G, Montalban-Bravo G, Garcia-Manero G, Issa GC, Chien KS, Jabbour E, Nasnas C, Huang X, Qiao W, Matthews J, Stojanik CJ, Patel KP, Abramova R, Thankachan J, Konopleva M, Kantarjian H, Ravandi F. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. *J Clin Oncol.* ePub 2024 Jan; :JCO2301911. PMID: 38277619.
  8. **Short, NJ**, Jabbour E, Macaron W, Ravandi F, Jain N, Kanagal-Shamanna R, Patel KP, Loghavi S, Haddad FG, Yilmaz M, Issa GC, Kebriaei P, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Kantarjian H. Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1. *Am J Hematol.* 2023 Aug; 98(8):1196-1203. PMID: 37183966.
  9. **Short NJ**, Kantarjian H, Ravandi F, Konopleva M, Jain N, Kanagal-Shamanna R, Patel KP, Macaron W, Kadia TM, Wang S, Jorgensen JL, Khoury JD, Yilmaz M, Kebriaei P, Takahashi K, Garcia-Manero G, Daver N, Post SM, Huang X, Kornblau SM, Pelletier S, Flores W, Matthews J, Garris R, Jabbour E. High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse. *Blood Adv.* 2022 Jul; 6(13):4006-4014. PMID: 35533262 PMCID
  10. **Short NJ**, Macaron W, Konopleva M, Ravandi F, Jain N, Issa GC, Kadia T, Sasaki K, Kebriaei P, Yilmaz M, Thompson PA, Takahashi K, Abbas HA, Wierda WG, Garris R, Kantarjian HM, Jabbour E. Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab. *Am J Hematol.* 2022 Jun; 97(6):E201-E204. PMID: 35266566.
-